17.83 +0.14 (0.79%)
After hours: 7:59PM EDT
|Bid||17.74 x 1100|
|Ask||17.83 x 4000|
|Day's Range||17.36 - 19.20|
|52 Week Range||17.36 - 32.50|
|PE Ratio (TTM)||17.16|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.50|
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.
In the second quarter of 2018, United Therapeutics (UTHR) generated revenues of $444.5 million compared to $444.6 million in the second quarter of 2017. Its net revenues remained flat YoY (year-over-year), but there was an increase in the number of patients being treated with United Therapeutics’ therapies. In the second quarter of 2018, United Therapeutics reported net income of $172.9 million compared to a net loss of $56 million in the second quarter of 2017.
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had net income of 28 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Index (PMI) data, output in the Healthcare sector is rising.
Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.
What Can Investors Expect from Exelixis’ Q2 2018 Results? In June, Exelixis (EXEL) announced that it would be added to the S&P MidCap 400 Index before the market opened on July 2. The S&P Dow Jones MidCap is one of the most highly reputed organizations, and its S&P MidCap 400 delivers investors a benchmark for midsize companies.
What Can Investors Expect from Exelixis’ Q2 2018 Results? Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1. Exelixis generated revenue of $134.2 million from product sales in the first quarter compared to $68.9 million in the first quarter of 2017.
Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.